Media about us

25 January 2016

Epic Sciences, Station X Link Up to Analyze CTC Data for CDx Development

GenomeWeb

Epic Sciences has announced it will use Station X's GenePool platform as part of data analysis for its collaborations with pharmaceutical companies to develop circulating tumor cell-based companion diagnostics.

22 January 2016

Georgia Bio Deals of the Year Spotlight Financings, Acquisitions and Collaboration

Business Wire

Georgia Bio announced its 2016 Deals of the Year for pharmaceutical, biotechnology, healthcare IT and medical device companies in the following categories – private financing, joint ventures, initial public offering, mergers, acquisitions and economic development – reflecting a broad range of activity. The annual Deal of the Year awards recognize transactions by life sciences companies in Georgia such as financings, partnering agreements and government grants that are significant to the state’s industry development.

20 January 2016

Never leave a cell behind

Lori Lesko / Cancer Research News, DDNews

Targeted toward cracking the code to treating disease resistance in tumor changes, Epic Sciences Inc. has partnered with the Penn Medicine Abramson Cancer Center on multiple studies to explore biomarkers, identified by the analysis of circulating tumor cells (CTCs) at a single-cell resolution. This process is predictive of response to personalized cancer therapeutics—and a precursor to the future of oncology.

19 January 2016

Companion Diagnostics Evolve

Chelsea Lacey-Mabe / Advanced healthcare Network

Out of seven billion people on this earth, no two people are the same. Companion diagnostics (CDx) providers argue their medicines shouldn't be the same either. In a world where someone can customize their sandwich, sneakers and even their physical appearance, the healthcare industry has realized one-size-fits-all treatments are no longer a good fit.

08 January 2016

FDA accepts application of cenicriviroc for primary sclerosing cholangitis

Healio

Tobira Therapeutics announced that the FDA and Health Canada have accepted its investigational new drug and clinical trial applications for review of cenicriviroc for the treatment of primary sclerosing cholangitis.

06 January 2016

Tobira: Undervalued With A Fast-Tracked NASH Compound

Seeking Alpha

TBRA has one drug candidate that shows promising results for treating NASH and HIV patients, with potential for other clinical applications due to the unique mechanism of action. TBRA faces moderate regulatory and management risks, and a higher financial risk which may exacerbate if more clinical trials take place with the current cash reserves. Overall, we think that TBRA is a moderately undervalued company, which will face a pivotal stage when the primary data from the lead trials come out in 2016.

04 January 2016

Syndax aligns with Merck KGaA and Pfizer on an immuno-oncology combo project

Damian Garde / Fierce Biotech

Privately held Syndax Pharmaceuticals is pairing its breakthrough-designated cancer drug with an in-development immunotherapy from Merck KGaA and Pfizer ($PFE), hoping to hit upon a winning clinical combination.

04 January 2016

Breast cancer biotech Syndax Pharmaceuticals refiles for an $86 million IPO

Renaissance Capital IPO Center

Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, refiled on Monday with the SEC to raise up to $86 million in an initial public offering.

18 December 2015

Marinus Pharmaceuticals Completes Enrollment in Phase 3 Trial For Ganaxolone Anti-Seizure Treatment

The Stock Informant

Marinus Pharmaceuticals (NASDAQ:MRNS), which focuses on the development of treatments for epilepsy and neuropsychiatric disorders, said it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures.

09 December 2015

Clearside closes $20M round for candidates that are injected into the eye's suprachoroidal space

Varun Saxena / FierceMedicalDevices

Ophthalmology company Clearside Biomedical just announced a $20 million Series C financing round to develop its proprietary formulation of triamcinolone acetonide that's delivered into the eye's suprachoroidal space via a microinjector, which it says is 10 times shorter than those used to administer drugs into the middle of the eye.